Regenxbio (NASDAQ:RGNX) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.22 by 45.45 percent. This is a 108.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $89.01 million which missed the analyst consensus estimate of $101.97 million by 12.71 percent. This is a 469.79 percent increase over sales of $15.62 million the same period last year.